France · Delayed Price · Currency is EUR PHAXIAM Therapeutics Company Description
PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing solutions to combat severe and resistant bacterial infections in France and the United States.
It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients.
The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa.
The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023.
PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.
| Country | France |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 68 |
| CEO | Thibaut Fayet |
Contact Details
Address: 60 Avenue Rockefeller Lyon, 69008 France | |
| Phone | 33 4 78 74 44 38 |
| Website | phaxiam.com |
Stock Details
| Ticker Symbol | PHXM |
| Exchange | Euronext Paris |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | FR001400K4B1 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jérôme Bailly Pharm.D. | Deputy Chief Executive Officer, Deputy GM, Chief Quality Officer and Qualified Person |
| Thibaut du Fayet | Chief Executive Officer |
| Frédéric Mathat | Chief Financial Officer |
| Cindy Fevre | Chief Scientific Officer |
| Naomi Eichenbaum | Director Investor Relations |
| Dr. Pascal Birman M.D. | Chief Medical Officer |
| Dr. Philip L. Lorenzi M.D., Ph.D. | Consultant and Member of Scientific Board |
| Prof. Eric Raymond M.D., Ph.D. | Consultant and Member of Scientific Board |
| Dr. Bridget Bax Ph.D. | Consultant and Member of Scientific Board |
| Prof. Arthur E. Frankel M.D., Ph.D. | Consultant and Member of Scientific Board |